Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 101.60$. Average daily volumn in 3 months 1.01M. Market cap 234.40B



Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 101.37$. Total volume : 309.89k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price
101.37$
Change
-0.40
Volume
309.89k

Previous Close101.77
Open100.94
Day Range100.50-101.69
Bid101.35 x 900
Ask101.41 x 800
Volume309.89k
Average Volume1.01M
Market Cap234.4B
Beta0.27
52 Week Range63.22-107.24
Trailing P/E34.33
Foward P/E30.53
Dividend (Yield %)1.45%
Ex-Dividend Date2021-08-16



Financial Details


According to Novo Nordisk A/S's financial reports the company's revenue in 2020 were 126.95B an increase( +3.28%) over the years 2019 revenue that were of 122.02B. In 2020 the company's total earnings were 42.14B while total earnings in 2019 were 38.95B( +10.53%).


Loading ...



Organization

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority of its voting shares.

Novo Nordisk A/S_logo

Market Cap:
234.40B
Revenue:
126.95B
Total Assets:
144.92B
Total Cash:
12.76B


News about "Novo Nordisk A/S"

Novo Nordisk A/S – Share repurchase programme_image

Novo Nordisk A/S – Share repurchase programme

Share repurchase programme Bagsværd, Denmark, 13 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the ...

Source from : YAHOO!Finance - 9 days ago


The Novo Nordisk Foundation funds the world's first interdisciplinary research center to convert CO2 in the atmosphere into sustainable raw materials

The Novo Nordisk Foundation has awarded €84.7 million to establish a new research center to identify innovative solutions to reduce the amount of CO2 in the atmosphere and technologies to recycle CO2.

Source from : YAHOO!Finance - 19 hours ago


Global Diabetes Drugs Market 2021 Future Forecast 2027 – Sanofi, Huadong Medicine, Astrazeneca, Novo Nordisk_image

Global Diabetes Drugs Market 2021 Future Forecast 2027 – Sanofi, Huadong Medicine, Astrazeneca, Novo Nordisk

The research report Global Diabetes Drugs Market is released by Market Research Place for the forecast period 2021 to 2027. The Diabetes Drugs report encapsulates the definition of the market, market ...

Source from : manometcurrent.com - 15 hours ago


Novo Nordisk, Roche see outsized threats from U.S. drug pricing talks: analysts_image

Novo Nordisk, Roche see outsized threats from U.S. drug pricing talks: analysts

While Congress and the U.S. government have sought to lower drug prices for years, the issue appears to be coming to a head once again in Washington, D.C. Analyzing the potential effects of such ...

Source from : FiercePharma - 9 days ago


Novo Nordisk, Broad Institute Partner to Uncover Genetic Links to Disease_image

Novo Nordisk, Broad Institute Partner to Uncover Genetic Links to Disease

The Novo Nordisk Foundation is partnering with the Broad Institute of MIT and Harvard University to launch a massive genetic data mining project that aims to gain deeper insight into how human genetic ...

Source from : PharmaLive - 5 days ago


USTA Foundation Awards $60,000 To Youth Players Through Novo Nordisk Donnelly Scholarship_image

USTA Foundation Awards $60,000 To Youth Players Through Novo Nordisk Donnelly Scholarship

The Novo Nordisk Donnelly Scholarship joined the USTA Foundation’s slate of scholarships in 2021. The Donnelly Scholarship has been funded for the past 18 years by Novo Nordisk Inc., a global ...

Source from : tennis-tourtalk - 11 days ago


Novo Nordisk Foundation teams up with Broad Institute, Harvard for diabetes, obesity research hub_image

Novo Nordisk Foundation teams up with Broad Institute, Harvard for diabetes, obesity research hub

The Novo Nordisk Foundation, part of the Danish pharma Novo Group, is stumping up $47.5 million for a new research collab between the Broad Institute of MIT and Harvard. Together, and with the seeding ...

Source from : FierceBiotech - 7 days ago


Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes_image

Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes

The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms.

Source from : MassDevice - 7 days ago


It’s Time for Time in Range – A New Resource for You and Your Healthcare Team_image

It’s Time for Time in Range – A New Resource for You and Your Healthcare Team

Tribe partnered with Abbott and Novo Nordisk to bring you the Time in Range Hub – a new online resource to help you and your healthcare providers learn about Time in Range. Read more about this ...

Source from : diaTribe - 2 days ago


Novo Nordisk Foundation and Broad Institute of MIT and Harvard launch new research center for genomic mechanisms of disease

The Novo Nordisk Foundation and the Broad Institute of MIT and Harvard announced today the launch of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative that will ...

Source from : Associated Press - 7 days ago


getWizer Selected for Novo Nordisk's Exclusive Innovation Program

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- getWizer is selected to be a part of Novo Nordisk's first cohort of the Novo Nordisk Global Business Services (GBS) Innovation Garage Fast Track Program.

Source from : PR Newswire - 21 days ago


Peptide Therapeutics Market – Are you Planning to Invest, Read the Report to have a Clear Picture of the Market with Players -Teva,Novo Nordisk_image

Peptide Therapeutics Market – Are you Planning to Invest, Read the Report to have a Clear Picture of the Market with Players -Teva,Novo Nordisk

Our team of research specialists at Decisive Markets Insights has published a stunning report on the Peptide Therapeutics Market which incorporates a 360-degree idea on its Supply Chain Analysis ...

Source from : List of Banks in Belarus - 6 days ago


Semaglutide prescription to be restricted to endocrinologists only: CDSCO panel tells Novo Nordisk_image

Semaglutide prescription to be restricted to endocrinologists only: CDSCO panel tells Novo Nordisk

In a major development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization to Novo Nordisk India for the ...

Source from : Daily - 11 days ago


Recombinant Human Growth Hormone Market – Major Technology Giants in Buzz Again | Novo Nordisk, Pfizer, Eli Lilly,_image

Recombinant Human Growth Hormone Market – Major Technology Giants in Buzz Again | Novo Nordisk, Pfizer, Eli Lilly,

Get PDF template of Recombinant Human Growth Hormone report @jcmarketresearch.com/report-details/1310504/sample Additionally, Recombinant Human Growth Hormone report provides a futuristic perspective ...

Source from : manometcurrent.com - 5 days ago


Novo Nordisk Launches Foundation Center for Genomic Mechanisms of Disease

Initiative, together with the Broad Institute of MIT and Harvard, aims to accelerate efforts to mine genetic data for insights into disease mechanisms.

Source from : Contract Pharma - 7 days ago


Rare diseases - Drug Trial, AstraZeneca, Novo Nordisk

As 2020 was drawing to a close, AstraZeneca announced the year’s largest M&A deal with a $39 billion… ...

Source from : The Pharma Letter - 3 days ago


CVS Health, Novo Nordisk Inc. join forces to provide enhanced, personalized support for obesity in retail settings

WOONSOCKET, R.I., and PLAINSBORO, N.J. - CVS Health (NYSE: CVS) and Novo Nordisk Inc. announced today that the two companies are piloting a new, personalized nutrition coaching program to support ...

Source from : publicnow.com - 5 days ago


Preventive Healthcare and Wellness Market Future Growth Outlook 2021-2027 | Phoenix Medicine., Aetna, Novo Nordisk_image

Preventive Healthcare and Wellness Market Future Growth Outlook 2021-2027 | Phoenix Medicine., Aetna, Novo Nordisk

Preventive Healthcare and Wellness Market is growing at a 27 30 CAGR during the forecast period 2021 2027 The increasing interest of the individuals in this industry is that the major reason for the ...

Source from : openpr.com - 10 days ago


Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 30 August 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ...

Source from : Yahoo Finance - 23 days ago


Novo Nordisk A/S Share repurchase programme

Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Source from : Middle East North Africa Financial Network - 1 month ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 19,301,886 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares ...

Source from : wallstreet online - 16 days ago


Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 6 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...

Source from : Yahoo Finance - 16 days ago


Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 23 August 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ...

Source from : Yahoo Finance - 1 month ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 18,497,886 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares ...

Source from : wallstreet online - 1 month ago


Novo Nordisk A/S Class B NOVC

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Source from : Morningstar%2c Inc. - 6 days ago


Novo Nordisk: Dominance In The Diabetes Market

I believe one of the main drivers for Novo Nordisk's (NVO) future growth revolves around the potential for diabetes and obesity trends to continue upward over the long term. I also believe that ...

Source from : Seeking Alpha - 21 days ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 18,897,886 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in ...

Source from : Privata Affärer - 23 days ago


Novo Nordisk A/S Series B

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 29 days ago


MIT, Novo Nordisk advance oral biologics delivery project

The search for a way to orally administer biologics has led Novo Nordisk to the leopard tortoise. By mimicking the shape of the tortoise’s shell, researchers at MIT and Novo have come up with an ...

Source from : FiercePharma - 22 days ago


Novo Nordisk

Novo Nordisk considering Seattle for new obesity R&D center by John Cook on September 18, 2014 September 18, 2014 at 7:18 am Subscribe to GeekWire's free newsletters to catch every headline ...

Source from : GeekWire - 26 days ago


Global Hemophilia Treatment Market Insights (2021 to 2026) - Featuring Novo Nordisk, Bayer HealthCare and Baxter Among Others - ResearchAndMarkets.com

Companies Mentioned Novo Nordisk Bayer HealthCare Wyeth Pharmaceuticals Baxter AG HUALAN BIO Shanghai RAAS Shanghai Institute of Biological Products For the competitor segment, the report includes ...

Source from : The Register-Herald - 21 days ago


Novo Nordisk Seattle Research Center

Look for highlights from the GeekWire Calendar each week on GeekWire, and check out GeekWire's own unique series of ... serious chronic disease, the Novo Nordisk Seattle Research Center ...

Source from : GeekWire - 26 days ago


Novo Nordisk A/S – Share repurchase programme

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 32,026 B shares in the period from 5 August 2021 to 13 August 2021. The shares in ...

Source from : Yahoo - 1 month ago


Novo Nordisk A/S (NVO) Q2 2021 Earnings Call Transcript

Please note that this call is being webcasted live and a recording will be made available on Novo Nordisk's website. The call is scheduled to last for one hour. Please turn to the next slide.

Source from : MSN - 1 month ago


Novo Nordisk A/S – Share repurchase programme

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 32,026 B shares in the period from 5 August 2021 to 13 August 2021. The shares in these ...

Source from : Yahoo Canada Sports - 1 month ago


Novo Nordisk earnings: here's what Wall Street expects

This story was written by Markets Insider's RoboEddy, which automatically writes these stories based on data provided by our partners. SHARE THIS POST Novo Nordisk NewsMORE Related Stocks Find ...

Source from : Business Insider - 1 month ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 17,552,912 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in ...

Source from : Privata Affärer - 1 month ago